CD123 Expression in Philadelphia-chromosome-Like B Acute Lymphoblastic Leukemia/Lymphoma

B acute lymphoblastic leukemia/lymphoma (B-ALL) is a hematologic malignancy derived from B-cell progenitors.1 Significant advances in therapy for B-ALL patients have taken place over the past decades. The outcome of pediatric B-ALL has improved dramatically with 10 year overall survival (OS) of>90%.2 Notwithstanding, B-ALL outcomes among adults remain inferior with 5-year OS rate between 30% and 50%.3 Therefore, novel therapeutic options are needed for adults with B-ALL.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 7, 2020 Category: Hematology Authors: Kirill A. Lyapichev, Narittee Sukswai, Evgeniya Angelova, Marian J. Kersh, Sherry Pierce, Marina Konopleva, Nitin Jain, Elias J. Jabbour, Jeffrey L. Jorgensen, Sa A. Wang, L. Jeffrey Medeiros, Joseph D. Khoury, Sergej Konoplev Tags: Commentary Source Type: research